stockrowJazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
Follow JAZZ
Alert me
Jazz Pharmaceuticals PLC (JAZZ) Return on equity
Jazz Pharmaceuticals PLC's return on equity over the twelve months to 30 September 2026 was 5.05%, up 13.5 percentage points from fiscal 2025 (−8.47%). Over the past ten years it has ranged from −8.65% (fiscal 2021) to 22.8% (fiscal 2016); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −8.47% | (23.05) |
| FY2024 | 14.6% | 1.69 |
| FY2023 | 12.9% | 19.25 |
| FY2022 | −6.36% | 2.29 |
| FY2021 | −8.65% | (15.70) |
| FY2020 | 7.05% | (10.79) |
| FY2019 | 17.8% | 1.49 |
| FY2018 | 16.4% | (4.90) |
| FY2017 | 21.3% | (1.58) |
| FY2016 | 22.8% | 0.64 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| HALO Halozyme Therapeutics, Inc. compare | 216.4% |
| ASND Ascendis Pharma A/S compare | 118.4% |
| EXEL Exelixis, Inc. compare | 44.3% |
| BBIO BridgeBio Pharma, Inc. compare | 26.2% |
| TECH Bio-Techne Corp compare | 9.03% |
| JAZZ Jazz Pharmaceuticals PLC | 5.05% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.31% |
| KYMR Kymera Therapeutics, Inc. compare | −27.3% |
| SMMT Summit Therapeutics PLC compare | −192.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on JAZZ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement